October 15, 2024

New Member: Welcome in our cluster to Daiichi Sankyo Europe GmbH

New Member: Welcome in our cluster to Daiichi Sankyo Europe GmbH
Go back

Daiichi Sankyo’s European roots date back to the 1980s with branches in Düsseldorf. In 1990, Sankyo acquired Luitpold-Werke, a German pharmaceutical company, expanding operations to Pfaffenhofen, Germany, and Altkirch, France. In 2006, Daiichi and Sankyo merged, with European headquarters in Munich. Now present in 13 countries, Daiichi Sankyo employs over 2,000 people, making it one of Europe’s largest Japanese pharmaceutical companies. It develops and markets treatments for hypertension, dyslipidemia, infections, cardiovascular diseases, and thrombotic disorders.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
Europe’s top health start-ups take centre stage: EIT Health Catapult winners are revealed at HLTH Europe

Europe’s top health start-ups take centre stage: EIT Health Catapult winners are revealed at HLTH Europe

The EIT Health Catapult 9th Edition competition winners were announced on 17 June at HLTH Europe 2025, the conference where global expertise meets local insight to address Europe’s unique healthcare challenges and opportunities. Previous edition winners and finalists have attracted significant interest from leading Life Sciences and HealthTech companies. EIT Health celebrated the next wave of health […]

read more
Parkinson’s disease: gut microbiome reveals environmental chemical footprints

Parkinson’s disease: gut microbiome reveals environmental chemical footprints

New meta-analysis uses machine learning tools to explore links between the gut microbiome and Parkinson’s disease Summary  Parkinson’s disease is a progressive and common neurodegenerative condition, typically characterised by involuntary shaking, stiffness, and slow movement. Beyond these motor symptoms, individuals often experience a range of non-motor issues, including significant gut problems such as constipation, inflammation, […]

read more
ERC ADVANCED GRANT VALUABLE FUNDING FOR FIVE RESEARCHERS AT UNIVERSITÄT HEIDELBERG

ERC ADVANCED GRANT VALUABLE FUNDING FOR FIVE RESEARCHERS AT UNIVERSITÄT HEIDELBERG

THE EUROPEAN RESEARCH COUNCIL FINANCES GROUNDBREAKING PROJECTS WITH ERC ADVANCED GRANTS Five scientists from Heidelberg University are each receiving valuable funding from the European Research Council (ERC), an ERC Advanced Grant. These grants are intended for top-flight researchers who are pursuing groundbreaking projects with their work. Two of the grants go to Prof. Dr Loredana […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp